TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03080896

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet
Description: intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope aScope III
Description: Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscope aScope III
Description: Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
Study: NCT02230033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
Study: NCT02453308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: 1. Artemether-lumefantrine for 3 days~2. Dihydroartemisinin-piperaquine for 3 days.~3. Artesunate-mefloquine for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACT
Description: 1. Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~2. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~3. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.
Study: NCT02926885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL LIVER RETRACTOR DEVICE
Description: LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXIBLE LIVER RETRACTOR DEVICE
Description: LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
Description: LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
Description: LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
Study: NCT02785523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganoderma Spore Lipids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Study: NCT00427765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test Dose = 32 mg/m\^2 IV for 1 Day; 130 mg/m\^2 IV for 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 IV for 2 Days
Study: NCT00905866

Intervention type: OTHER
Intervention: PAS and SF-36 questionnaires
Description: Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
Study: NCT02503137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical SM04554 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical SM04554 solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vehicle solution
Study: NCT02281513

Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone Application
Description: Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity

Intervention type: OTHER
Group type: OTHER
Intervention: Fitbit Activity Monitor
Description: Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Coaching Sessions
Description: Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
Study: NCT01055431

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control bread
Description: Control bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teff Bread
Description: Teff bread
Study: NCT04257929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitolisant oral tablets
Description: Pitolisant 4.45 mg or 17.8 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitolisant oral tablets
Description: Pitolisant 4.45 mg or 17.8 mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Pitolisant oral tablets
Description: Pitolisant 4.45 mg or 17.8 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching placebo tablets
Study: NCT02654769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate (Picato®)
Description: Brand product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Ingenol Mebutate
Description: Generic formulated to have the same therapeutic effect of the brand

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
Study: NCT00557713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1. -Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~2. -Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~3. -Surgery (6-8 weeks after last bevacizumab dose)~4. -Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)
Study: NCT02790411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging devices
Description: technological adjustment tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Non Invasive Devices
Description: Tests with REX BIONICS Exoskeleton
Study: NCT00737672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface
Description: Deployment of investigational stent graft at the venous anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty
Description: Percutaneous Transluminal Angioplasty at the venous anastomosis
Study: NCT00943618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling/Phone Calls
Description: Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling/Phone Calls
Description: Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling/Phone Calls
Description: Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
Study: NCT03487432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super High-Pressure NC PTCA Balloon (OPN NC)
Description: Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoring PTCA Balloon (NSE Alpha)
Description: Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
Study: NCT00446004

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib Mesylate
Description: Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib Mesylate
Description: Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
Study: NCT03646097

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-PCI
Description: PCI only with angiography and without OCT findings

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-PCI
Description: PCI with OCT-measurements but no transfer of landingzone-markers to angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACR-PCI
Description: PCI with OCT-measurements and transfer of landingzone-markers to angiography
Study: NCT00516516

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine, 1g orally, twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, similar in appearance to study tablets, given orally, twice daily.
Study: NCT00996853

Intervention type: OTHER
Intervention: Safety follow up
Description: Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
Study: NCT03262480

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stroke volume optimization
Description: Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stroke volume optimization
Description: Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2.
Study: NCT00337480

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
Study: NCT04129567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humidified oxygen
Description: Delivering humidified oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry oxygen
Description: Delivering dry oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Humidified air
Description: Delivering humidified air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry air
Description: Delivering dry air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
Study: NCT04416841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Description: Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness Walking
Description: Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Diabetic Care Education
Description: Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
Study: NCT03366077

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Probiotic
Study: NCT01088724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine, cyclophosphamide, doxorubicin, rituximab
Description: Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
Study: NCT00923572

Intervention type: DRUG
Intervention: EE30/DRSP (Yasmin, BAY86-5131)
Description: Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
Study: NCT01939418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Afinitor 5mg qd. po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
Study: NCT00633113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MPPA
Description: - Medial Parapatellar Arthrotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SV
Description: - Subvastus Technique
Study: NCT01260402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resynchronization using a transeptal approach
Description: Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.~Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resynchronization using a coronary sinus approach
Description: Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.~Devices used for procedure : RADI PressureWire, routine catheters chosen by operator
Study: NCT01881828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (glucophage)
Description: The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Study: NCT00923793

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium implant (CranioConstruct™)
Description: One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydroxylapatite (CustomBone)
Description: Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
Study: NCT01930006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Study: NCT01369888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m\^2, intravenous (IV) (in the vein) x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m\^2, intravenous (IV) (in the vein) x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m\^2, intravenous (IV) (in the vein) x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m\^2, intravenous (IV) (in the vein) x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: IV over 30 minutes on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: IV over 30 minutes on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: IV over 30 minutes on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: IV over 30 minutes on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-15
Description: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-15
Description: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-15
Description: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-15
Description: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.